Lekowrazliwosc szczepow Pseudomonas aeruginosa wyizolowanych od pacjentow szpitala i specjalistycznych poradni SP ZOZ w Nidzicy

W ciągu ponad trzech lat (wrzesień 2000 r. - grudzień 2003 r.) wyhodowano 296 szczepów Pseudomonas aeruginosa z próbek materiału klinicznego oraz 96 szczepów z próbek materiału ambulatoryjnego (razem 392). Szczepy były izolowane od pacjentów oddziałów szpitalnych i specjalistycznych poradni SP ZOZ w Nidzicy. W pracy dokonano analizy Iekowrażliwości zidentyfikowanych szczepów Pseudomonas aeruginosa. Największą aktywność in vitro wobec klinicznych szczepów pałeczki ropy błękitnej wykazał antybiotyk kar- bapenemowy - imipenem. Znaleziono jeden szczep oporny na imipenem (0,3%). Beta-laktamazę o rozszerzonym spektrum substratowym (ESBL) wytwarzało 7,4% szczepów Pseudomonas aeruginosa.

The aim of this study was to evaluate a frequency of isolation and antimicrobial susceptibility testing (AST) of Pseudomonas aeruginosa strains cultured from clinical specimens collected from patients hospitalized in wards and specialistic outpatients clinics of a hospital in Nidzica (01 09 2000 -31. 12. 2003). During over three years 392 Pseudomonas aeruginosa strains were cultured from 16346 clinical samples provided to bacteriological laboratory. P. aeruginosa strains were isolated from 2.5% of examined specimens. Susceptibility of Pseudomonas aeruginosa strains to antimicrobial agents was tested. The highest in vitro activity against clinical P. aeruginosa strains demonstrated imipenem. One strain was resistant to imipenem. This strain was isolated from a patient of a surgical department. Metalo-beta-Iactamase was not detected (MBL-negative strain).Twenty nine strains were ESBL producer (7.4% of all strains). The contribution of Pseudomonas aeruginosa strains to the etiology of nosoconial and ambulatory infections increases. In vitro activity of antibacterial agents against P. aeruginosa strains should be monitored during therapy of infections. Resistance to antibiotics/chemothe-rapeutics may be acquired during treatment with antibacterial agent to which P. aeruginosa strain was susceptible according to the antibiogram.